C反应蛋白基因多态性与脑梗死的相关性研究

目的:通过脑梗死患者检验观察,研究C反应蛋白基因多态性与脑梗死的相关性。方法:回顾笔者所在医院2010-2011年收治的70例脑梗死患者,经过检查确诊动脉硬化性血栓性脑梗患者46例,腔隙性脑梗患者24例,将其分为血栓组和腔隙组。两组患者于入院后即抽取空腹静脉血3ml,用散射速率法测定C反应蛋白含量(hs-CRP)、总胆固醇(CHO)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)、极低密度脂蛋白(VLDL)测定。为避免操作误差,均选择同一人检查。结果:两组患者入院后检查结果比较,hs-CRP和VLDL两项比较差异有统计学意义(P<0.05),其他检验项目比较差异无统计学意义(P>0.05),血栓组根据病情严重度,分为轻、中、重度,通过三组检查发现,轻、中、重度hs-CRP有递增趋势,且各程度比较,差异均有统计学意义(P<0.05)。两组患者经过平衡检验,均符合Hardy-Weinberg平衡定律。通过对比可见,血栓组CRP-717A>GAA基因型频率明显高于腔隙组;血栓组AG+GG基因型频率低于腔隙组,差异有统计学意义(P<0.05)。结论:CRP-717A>G基因多态性与脑梗死具有相关性,但限于病例人数局限,且hs-CRP受多方因素影响,检验不能代表更大层次面,但可以说明,对于脑梗死患者及早观察CRP,不但有更好确定病情指导治疗意义,还可以为预防疾病发生做预防性治疗。

汉族人群胆固醇酯转运蛋白基因和C反应蛋白基因多态性与非瓣膜性房颤的关联

目的研究胆固醇酯转运蛋白（cholesteryl ester transfer protein，CETP）基因TaqIB、C反应蛋白（Creactive protein，CRP）基因1444C／T单核苷酸多态性（single nonucleotide polymorphism，SNP）与汉族非瓣膜性房颤的相关。方法选取非瓣膜性房颤患者147例、病例对照147例，应用聚合酶链反应一限制性内切酶片段长度多态性鉴定基因型。结果CETP TaqIB（P=0.005，OR=0.614，B=-0、488）和CRP 1444C／T（P=0.003，0R=2.428，β=0.887）遗传多态性在病例组和对照组间差异有统计学意义。根据性别分组：女性组，吸烟、CETP TaqIS、CRP 1444C／T病例对照间差异有统计学意义；男性组，体重指数和CETP TaqlB病例对照间差异有统计学意义。结论中国汉族CETP TaqlB（B2等位基因为保护性因子）和CRP 1444C／T（T等位基因为危险因子）多态性可能与非瓣膜性房颤相关。吸烟、CRP 1444C／T多态性可能增加女性非瓣膜性房颤遗传易感性；肥胖可能增加男性非瓣膜性房颤遗传易感性。

奶牛CRP基因SNP的生物信息学分析

利用PCR-SSCP方法检测了CRP基因在中国荷斯坦奶牛群体中的单核苷酸多态性,并用各种网络分析软件分析了单核苷酸改变对其功能的影响。结果表明:CRP基因在P1引物扩增片段中存在PCR-SSCP多态性并引起编码氨基酸的改变。经测序分析可知,位于P1引物扩增片段内存在G→T突变,该突变位点使编码的氨基酸发生Q→H的改变。对引起编码氨基酸的P1位点进一步进行生物信息学分析发现,由于编码的改变引起新的转录结合们点vaccinia-term-s的产生,但没有引起其它CRP二三级结构的变化。这一分析结果可为奶牛CRP基因突变所产生的性状功能的改变提供分子水平的解释。

Reactive protein, plasminogen activator inhibitor type-1 （PAI-1） levels, PAI-1 promoter 4G/5G polymorphism and acute myocardial infarction

Objective To investigate the relationship between CRP, plasminogen activator inhibitor type 1 （PAI-1） levels, PAI-1 gene promoter 4G/5G polymorphism and the type of acute myocardial infarction （ST elevation myocardial infarction, STEMI vs the non-ST elevation Myocardial infarction, NSTEMI）. Methods One hundred seventy-six consecutive patients with AMI were included for the study, of whom 60 had STEMI and 56 had NSTEMI, and 60 adults without cardiovascular and cerebrovascular disease were selected as controls. Blood samples were obtained from patients within 6 h of AMI and the plasma PAI-1, CRP, and the gene polymorphism were measured. Results Plasma levels of PAI- 1 and CRP were higher in AMI groups, compared those in the control group, and plasma levels of PAI-1 were significantly higher in patients with STEMI compared to those with NSTEMI （80.12ng/ml VS.73.01ng/ml, P 〈0.01）, while CRP levels were not significantly different between patient with STEMI and NSTEMI （3.87 ± 0.79 mg/ml VS.4.01 ±0.69mg/ml, P〉0.05）. PAI-1 levels presented a significant correlation with CRP levels in the NSTEMI subjects. However, PAI-1 and CRP levels could explain the lack of a significant relationship between them in control and STEMI subjects.The frequencies of 4G/4G genotype in the AMI group were higher than those in the control group and higher in patient with STEMI than in patient with NSTEMI. Plasma levels of PAI-1 in subjects with 4G/4G genotype were significantly increased as compared to those in subjects with 4G/5G and 5G/5G genotype. Conclusions Plasma PAI-1 levels were associated with different myocardial infarction type, and PAI-1 promoter 4G/5G polymorphisms and CRP may be related to plasma PAI-1 levels

瑞舒伐他汀对动脉粥样硬化斑块中补体因子H表达的影响

目的研究瑞舒伐他汀对载脂蛋白E基因缺陷小鼠(ApoE-/-小鼠)动脉粥样硬化处补体因子H(CFH)表达的影响。方法 8周龄ApoE-/-小鼠随机分为4组:模型组Ⅰ(高脂饲料喂养10周)、模型组Ⅱ(高脂饲料喂养20周)、预防组(在给予高脂饲料的同时予瑞舒伐他汀预防性给药10周)和治疗组(于高脂饲料喂养10周后,给予瑞舒伐他汀,喂至20周)。阶段试验结束时取主动脉做HE染色及免疫组化,检测CFH mRNA转录和蛋白表达水平;检测血脂及血清hsCRP、C3a水平。结果与模型组Ⅰ和模型组Ⅱ比较,预防组及治疗组ApoE-/-小鼠主动脉内膜和斑块内CFH表达增多;CFH的mRNA转录水平和蛋白表达水平升高;血脂、hsCRP、C3a水降低(P<0.01或0.05)。结论瑞舒伐他汀降低血脂水平,降低动脉粥样硬化的炎症免疫反应,增加CFH表达。